灵活调整阿达木单抗剂量对中重度斑块状银屑病患者长期结局的优化
该开放标签研究纳入曾接受阿达木单抗治疗的银屑病患者,初始每两周40mg治疗24周后,PASI应答<50%者可增至每周40mg,达到PASI 75后减回每两周。第24周时64.1%患者达到PASI 75。剂量增加未伴随额外安全性问题,临时增量有助于实现并长期维持临床改善。
要点
- 第24周时,总体人群中64.1%达到PASI 75应答,40.3%达到PASI 90,21.7%达到PASI 100。
- 第24-252周期间PASI<50%的349例(27.8%)患者剂量增至每周一次。
- 剂量增加未伴随额外安全性问题。
核心结论
- 对每两周40mg阿达木单抗应答不充分的银屑病患者,临时将剂量增至每周一次有助于实现并长期维持临床改善。
研究设计与样本
- 开放标签研究,纳入曾在2/3期研究及其扩展研究中接受阿达木单抗治疗的银屑病患者,总体人群n=1256。
- 患者初始接受阿达木单抗40mg每两周一次治疗24周。
- 第24-252周,PASI应答<50%者可剂量增至40mg每周一次,并在6周、12周及此后每12周重新评估。
- 剂量增加后达到PASI 75应答者减回每两周一次,若应答再次低于PASI 50可重新增至每周一次,不允许进一步减量。
主要发现
- 第24周时,总体人群(n=1256)中64.1%达到≥PASI 75应答,40.3%达到≥PASI 90应答,21.7%达到PASI 100应答。
- 第24-252周期间PASI<50%的患者为349/1256(27.8%),剂量增至每周一次。
- 剂量增加的患者中,182例(52.1%)维持每周一次给药,167例(47.9%)达到PASI 75应答并减回每两周一次。
- 83例患者 later 因PASI<50%应答重新增至每周一次给药。
- 剂量增加未伴随额外安全性问题。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The recently updated dosing recommendation for adalimumab for moderate to severe plaque psoriasis states that patients with inadequate response to adalimumab every other week (EOW) after 16 weeks may benefit from an increase in dosing frequency to 40 mg every week (EW). OBJECTIVE: To determine the long-term efficacy of adalimumab in patients with psoriasis with flexibility to escalate and de-escalate between EOW and EW dosing. METHODS: Data from an open-label study in patients with psoriasis who had received adalimumab in phase 2/3 studies and their extensions were included. Patients initially received 40 mg adalimumab EOW for 24 weeks. From weeks 24-252, patients whose Psoriasis Area and Severity Index response was <50% (PASI 50) could have their dose-escalated to 40 mg EW and were re-evaluated at 6 and 12 weeks and then every 12 weeks thereafter. Patients who had their dose-escalated and achieved a PASI 75 response were de-escalated to EOW and could re-escalate to EW if response fell below PASI 50 again; no further de-escalation was allowed. Changes in PASI scores were reported at the last visit before dose escalation or de-escalation. RESULTS: By week 24, 64.1% of patients in the overall population (n = 1256) achieved ≥PASI 75 response, 40.3% ≥PASI 90 response and 21.7% PASI 100 response. Patients who had a <PASI 50 during weeks 24-252 (349/1256, 27.8%) had their dose-escalated to EW; 182 (52.1%) remained on EW dosing and 167 (47.9%) achieved a PASI 75 response and were de-escalated to EOW; 83 patients were later re-escalated to EW dosing owing to a <PASI 50 response. Dose escalation was not associated with additional safety concerns. CONCLUSION: Optimizing therapy by temporarily increasing the dosing of adalimumab to EW in patients with psoriasis and an inadequate response to adalimumab 40 mg EOW permitted the achievement and long-term maintenance of clinical improvement.
引用
- Gniadecki R, Leonardi CL, Gordon KB, et al. Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2018. PMID: 29524255. doi:10.1111/jdv.14926
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。